CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial‑mesenchymal transition

Yang,Gang; Wang,Guan; Xiong,Yongfu; Sun,Ji; Li,Weinan; Tang,Tao; Li,Jingdong

doi:10.3892/mmr.2021.12122

CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial‑mesenchymal transition

Authors:
- Gang Yang
- Guan Wang
- Yongfu Xiong
- Ji Sun
- Weinan Li
- Tao Tang
- Jingdong Li
View Affiliations

Affiliations: Department of Hepatocellular Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637007, P.R. China, Physical Examination Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637007, P.R. China
Published online on: April 27, 2021 https://doi.org/10.3892/mmr.2021.12122
Article Number: 483
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a type of primary liver cancer, which is associated with high mortality. HCC is one of the most common malignant tumors worldwide. Cell division cycle 20 (CDC20) has been reported to be associated with the development of various malignant tumors and epithelial‑mesenchymal transition (EMT) has been reported to be involved in the malignant metastasis of HCC. Therefore, the present study hypothesized that CDC20 may participate in the malignant biological behavior of HCC via EMT. The present study analyzed the expression levels of CDC20 in HCC and the association between CDC20 and poor prognosis. Furthermore, the effects of CDC20 on the proliferation, invasion and migration of HCC cells were examined using proliferation, migration and invasion assays. Finally, alterations in EMT were analyzed. The results revealed that CDC20 was highly expressed in HCC and HCC cell lines (P<0.05), and its high expression level was significantly associated with poor prognosis in patients with HCC (P<0.05). CDC20 silencing inhibited the proliferation, migration and invasion of HCC cells. Furthermore, CDC20 silencing increased the expression levels of E‑cadherin, and decreased the expression levels of N‑cadherin, vimentin and Ki‑67. In conclusion, the present study reported that CDC20 may be a novel therapeutic target in HCC and CDC20 could promote the progression of HCC by regulating EMT.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2004. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
5	Greten TF, Wang XW and Korangy F: Current concepts of immune based treatments for patients with HCC: From basic science to novel treatment approaches. Gut. 64:842–848. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kapanidou M, Curtis NL and Bolanos-Garcia VM: Cdc20: At the Crossroads between chromosome segregation and mitotic exit. Trends Biochem Sci. 42:193–205. 2017. View Article : Google Scholar : PubMed/NCBI
7	Schrock MS, Stromberg BR, Scarberry L and Summers MK: APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis. Semin Cancer Biol. 67:80–91. 2020. View Article : Google Scholar : PubMed/NCBI
8	Dong S, Huang F, Zhang H and Chen Q: Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. Biosci Rep. Feb 26–2019.doi: 10.1042/BSR20182306. View Article : Google Scholar
9	Parmar MB, K C RB, Löbenberg R and Uludağ H: Additive polyplexes to undertake siRNA therapy against CDC20 and Survivin in breast cancer cells. Biomacromolecules. 19:4193–4206. 2018. View Article : Google Scholar : PubMed/NCBI
10	De K, Grubb TM, Zalenski AA, Pfaff KE, Pal D, Majumder S, Summers MK and Venere M: Hyperphosphorylation of CDH1 in glioblastoma cancer stem cells attenuates APC/C ^CDH1 activity and pharmacologic inhibition of APC/C ^CDH1/CDC20 compromises viability. Mol Cancer Res. 17:1519–1530. 2019. View Article : Google Scholar : PubMed/NCBI
11	Kim Y, Choi JW, Lee JH and Kim YS: Spindle assembly checkpoint MAD2 and CDC20 overexpressions and cell-in-cell formation in gastric cancer and its precursor lesions. Hum Pathol. 85:174–183. 2019. View Article : Google Scholar : PubMed/NCBI
12	Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J, Lu M, Peng S, Qiu J and Gao X: Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. Int J Oncol. 49:1679–1685. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhang Q, Huang H, Liu A, Li J, Liu C, Sun B, Chen L, Gao Y, Xu D and Su C: Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells. EBioMedicine. 42:397–440. 2019. View Article : Google Scholar : PubMed/NCBI
14	Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
15	Diepenbruck M and Christofori G: Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no, maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
16	Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
17	Wu H, Zhang W, Wu ZR, Liu Y, Shi Y, Gong J, Shen W and Liu C: MiR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death Dis. 10:482019. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
20	Zhou Z, He M, Shah AA and Wan Y: Insights into APC/C: From cellular function to diseases and therapeutics. Cell Div. 11:92016. View Article : Google Scholar : PubMed/NCBI
21	McLean JR, Chaix D, Ohi MD and Gould KL: State of the APC/C: Organization, function, and structure. Crit Rev Biochem Mol Biol. 46:118–136. 2011. View Article : Google Scholar : PubMed/NCBI
22	Cheng S, Castillo V and Sliva D: CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity. Int J Oncol. 54:2250–2256. 2019.PubMed/NCBI
23	Alfarsi LH, Ansari RE, Craze ML, Toss MS, Masisi B, Ellis IO, Rakha EA and Green AR: CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Res Treat. 178:535–544. 2019. View Article : Google Scholar : PubMed/NCBI
24	Wang J, Zhou F, Li Y, Li Q, Wu Z, Yu L, Yuan F, Liu J, Tian Y, Cao Y, et al: Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. Cell Cycle. 16:2355–2365. 2017. View Article : Google Scholar : PubMed/NCBI
25	Chu Z, Zhang X, Li Q, Hu G, Lian CG and Geng S: CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the Wnt/β-catenin signaling pathway. Int J Oncol. 54:1534–1544. 2019.PubMed/NCBI
26	Sun C, Li M, Feng Y, Sun F, Zhang L, Xu Y, Lu S, Zhu J, Huang J, Wang J, et al: MDM2-P53 signaling pathway-mediated upregulation of CDC20 promotes progression of human diffuse large B-cell lymphoma. Onco Targets Ther. 13:10475–10487. 2020. View Article : Google Scholar : PubMed/NCBI
27	Couri T and Pillai A: Goals and targets for personalized therapy for HCC. Hepatol Int. 13:125–137. 2019. View Article : Google Scholar : PubMed/NCBI
28	Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
29	Yeung KT and Yang J: Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
30	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
31	Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
32	Yu M, Xue H, Wang Y, Shen Q, Jiang Q, Zhang X, Li K, Jia M, Jia J, Xu J and Tian Y: MiR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. Int J Oncol. 50:975–983. 2017. View Article : Google Scholar : PubMed/NCBI
33	Qiu E, Gao Y, Zhang B, Xia T, Zhang Z and Shang G: Upregulation of cell division cycle 20 in cisplatin resistance-induced epithelial-mesenchymal transition in osteosarcoma cells. Am J Transl Res. 12:1309–1318. 2020.PubMed/NCBI
34	Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, Mo Q, Liao L and Xu J: Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene. 36:1157–1166. 2017. View Article : Google Scholar : PubMed/NCBI